首页> 外文期刊>tropical journal of pharmaceutical research >Effect of immunotherapy on T lymphocyte subsets, FOXP3 and IFN-gamma/IL-4 ratio in children with allergic asthma
【24h】

Effect of immunotherapy on T lymphocyte subsets, FOXP3 and IFN-gamma/IL-4 ratio in children with allergic asthma

机译:免疫疗法对过敏性哮喘儿童T淋巴细胞亚群、FOXP3和IFN-γ/IL-4比值的影响

获取原文
获取原文并翻译 | 示例

摘要

Purpose: To study the effect of specific immunotherapy on T lymphocyte subsets, FOXP3 and IFN-gamma/IL-4 in children with allergic asthma (AA). Methods 57 AA children were selected and received the allergen specific immunotherapy, thereafter, the T lymphocyte subsets, FOXP3 and IFN-gamma/IL-4 ratio were measured at three time points, before treatment, after 1yr and 2yr of treatment. Then the clinical efficacy after 2yr was recorded. Results The pre- and post- treatment percentages of CD4 (+) CD25 (+) T cells in CD4 (+) T cells had no difference (P>0.05). The proportion of CD4 (+) CD25 (high) T cells in CD4 (+) T was significantly increased after 1yr and 2yr of treatment (P<0.05), the difference between that after 1yr and 2yr of treatment was not significant. The relative expression of FOXP3 at three time points in a descending order was after 1yr, 2yr of treatment and pre-treatment (P<0.05). The relative IFN-gamma expression after 1yr of treatment increased and returned to pre-treatment level after 2yr of treatment; IL-4 expression levels decreased as the treatment time extended; The IFN-gamma/IL-4 ratio at three time points in a descending order was after 1yr, 2yr of treatment and pretreatment (P<0.05). The levels of IL-4 and IFN-gamma in the children increased significantly as treatment time extended (P<0.05), and became stable after 1yr and 2yr of treatment, while the concentration of IL-4 showed a decrease trend (P<0.05), also tended to be stable after 1yr and 2yr of treatment. The clinical efficacy after 2yr of treatment was 87.72. Conclusion This study has revealed that FOXP3, IFN-gamma, and IL-4 have significant roles FOXP3 in the process of specific immunotherapy for children with allergic asthma. Further studies are needed to explore the mechanism.
机译:目的:探讨特异性免疫治疗对过敏性哮喘(AA)患儿T淋巴细胞亚群、FOXP3和IFN-γ/IL-4的影响。方法 选取57例AA患儿接受过敏原特异性免疫治疗,分别在治疗前、治疗后1年和2年3个时间点检测T淋巴细胞亚群、FOXP3和IFN-γ/IL-4比值。记录2年后的临床疗效。结果 CD4 (+) CD25 (+) T细胞处理前后的百分比与CD4 (+) T细胞处理后百分比差异无统计学意义(P>0.05)。处理1年和2年后CD4(+)CD25(高)T细胞比例显著增加(P<0.05),处理1年和2年后差异不显著。FOXP3在3个时间点的相对表达量从大到大依次为处理1年、2年后和处理前(P<0.05)。处理1年后IFN-γ相对表达量升高,处理2年后又恢复到处理前水平;IL-4表达水平随着治疗时间的延长而降低;3个时间点的IFN-γ/IL-4比值从大到大依次为处理1年、2年和预处理后(P<0.05)。随着治疗时间的延长,儿童IL-4和IFN-γ水平显著升高(P<0.05),治疗1年和2年后趋于稳定,而IL-4浓度呈下降趋势(P<0。05),治疗1年和2年后也趋于稳定。治疗2年后临床有效率为87.72%。结论 本研究揭示,FOXP3、IFN-γ和IL-4在儿童过敏性哮喘特异性免疫治疗过程中具有显著作用。需要进一步的研究来探索其机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号